Optimi Lays Out 2027 Psilocybin/MDMA Trial Plans; Settles US$240K CEO Pay in Shares
OPTH is trading near its 52-week low of $1.9 (8.4% above the low).
Summary
Optimi detailed 2027 plans for a redesigned 200-patient Phase 2b psilocybin depression trial and a 100-patient MDMA PTSD Phase 3, and will issue 114,285 shares at US$2.10 to settle US$240,000 of CEO compensation.
Key Events · Product Development and Regulatory · OPTH
-
OPTI-101 Trial Redesigned as Phase 2b
A protocol amendment converts the single-arm, open-label study into a randomized, double-blind, active placebo-controlled trial in 200 adults with severe MDD (MADRS ≥30); it is under Health Canada review.
-
Dosing Q1 2027, Data 2028
Enrollment and dosing are expected to begin Q1 2027, with topline data in 2028 and 12-month durability data to follow; no interim efficacy analysis is planned.
-
MDMA PTSD Phase 3 Set for 2027
Optimi assumes sponsorship of a 100-patient open-label Phase 3 in veterans and front-line workers under a Health Canada No Objection Letter, with a U.S. IND planned for 2027.
-
CEO Paid in Shares, Not Cash
114,285 shares at US$2.10 settle US$240,000 of accrued CEO compensation (Oct 2024-Oct 2026); a related-party transaction subject to a four-month-and-one-day hold and a definitive agreement.
Analysis · OPTH · Life Sciences
Optimi has converted its lead psilocybin program from a small open-label study into a 200-patient randomized, double-blind Phase 2b in severe depression — a materially more expensive and more statistically credible design. Dosing will not start until Q1 2027, with topline data not until 2028, pushing any potential approval story years out. The company says it will fund the trial from cash on hand, so the burn rate matters. The MDMA PTSD Phase 3 (100 patients) and planned U.S. INDs add optionality but no near-term revenue. The shares-for-debt piece is small in dollars but notable for governance: the CEO is being paid in stock at US$2.10 (above today's $2.06), which preserves cash but adds 114,285 shares and is a related-party transaction.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12M. The 52-week trading range was $1.90 to $8.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.